Site-specific photobiotinylation of immunoglobulins, fragments and light chain dimers

被引:17
作者
Pavlinkova, G
Rajagopalan, K
Muller, S
Chavan, A
Sievert, G
Lou, DY
OToole, C
Haley, B
Kohler, H
机构
[1] UNIV KENTUCKY,DEPT MICROBIOL & IMMUNOL,LEXINGTON,KY 40436
[2] UNIV KENTUCKY,DIV MED CHEM & PHARMACEUT,LEXINGTON,KY 40436
[3] UNIV KENTUCKY,COLL PHARM,DEPT MED,LEXINGTON,KY 40436
[4] UNIV KENTUCKY,LUCILLE P MARKEY CANC CTR,LEXINGTON,KY 40436
[5] IMMPHERON INC,LEXINGTON,KY 40436
关键词
photoaffinity labeling; antibody; site-specific biotinylation;
D O I
10.1016/S0022-1759(96)00214-1
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Herein we report a new method to rapidly photoinsert biotin into a specific and highly conserved site on the Ig structure using a mild photochemical activation step. This site resides in the Fv fragment and involves invariant residues which provide base stacking interactions to the purine ring of ATP (Rajagopalan et al. (1996) Proc, Natl. Acad. Sci, USA 93, 6019-6024), Biotin was coupled to either the phosphate or the ribose of the 8-azidopurine nucleotide or nucleoside photoaffinity probe and shown to insert into the affinity site efficiently. Several monoclonal and polyclonal antibodies, as well as enzymatic and recombinant antibody fragments and light chain dimers were photoaffinity biotinylated and used in ELISA, FAGS and Western blots. The selectivity of this site-specific biotinylation method also allows for biotinylation of antibodies in culture supernatants and immune sera without prior purification. Because the biotinylation takes place under physiological conditions and within a short time period, photobiotinylation would be the preferred method for antibodies which are easily damaged by classical non-site specific random biotinylation chemistry.
引用
收藏
页码:77 / 88
页数:12
相关论文
共 16 条
[1]  
Czarnecki J, 1979, Methods Enzymol, V56, P642
[2]  
JOHNSON VG, 1986, CANCER RES, V46, P850
[3]  
KHATOON S, 1989, ANN NEUROL, V26, P215
[4]  
LEVY MB, 1985, ANN ALLERGY, V54, P167
[5]  
MALONEY DG, 1985, HYBRIDOMA, V4, P4479
[6]  
MULLER S, 1991, J IMMUNOL, V147, P933
[7]  
MURANO R, 1983, CANCER RES, V48, P736
[8]  
PAGANELLI G, 1992, EUR J NUCL MED, V19, P322
[9]  
POTTER RL, 1983, METHOD ENZYMOL, V91, P13
[10]  
RAJAGOPALAN K, 1993, J BIOL CHEM, V268, P14230